Cellectis announces the settlement and delivery of its ADS offering and the exercise of the over-allotment option of the guarantor banks

by

NEW YORK, 07 Feb. 11, 2023 (GLOBE NEWSWIRE) — Cellectis (“Cellectis” or the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company, which uses its genome-editing platform to deliver cell therapies and genes that save lives, announced today:

    CLLS99 – FO 2023 Press Release – Closing and Greenshoe (French)(1535386016.2) (1).pdf


Photo of author

Alexandra Hartman Editor-in-Chief

Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.

The US Navy releases the first photos of the Chinese airship’s recovery

at least one hundred Leopard 1 tanks will be delivered by Berlin

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.